Video

Dr. Keith Keer on PD-L1 in Lung Cancer

​Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.

Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.

Right now the only biomarker with validated data in lung cancer is PD-L1 immunohistochemistry. It is perceived as not being a good biomarker, but it is unfairly judged says Kerr.

It often gets compared to EGFR mutation or ALK translocation which are very effective biomarkers, but PD-L1 is not the only controlling factor within the immune response and it will never have the level of predictive power as those biomarkers. Expectations of PD-L1 need to be downgraded, says Kerr.

However, it can be improved. Right now each PD-L1 inhibitor has its own immunohistochemistry test and they are not all the same. It is not practical to do multiple test, so there needs to be simplification, says Keer.

Related Videos
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC
Al Malki
Ian Krop MD, PhD
Timothy S. Fenske, MD, MS
Ignacio Garrido-Laguna, MD, PhD, MBA
Marwan G. Fakih, MD
Dr Alderuccio on Loncastuximab Tesirine With Rituximab in R/R Follicular Lymphoma
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
Werutsky